Vantage Consulting Group’s Coherus Oncology CHRS Stock Holding History

Vantage Consulting Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,712	Closed	-$65K	–	380
2020 Q4	$65K	Buy	+3,712	New	+$66.1K	0.01%	347

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vantage Consulting Group's CHRS Position: Q1 2021 in Review

Vantage Consulting Group sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 3,712 shares — an estimated $65K sold.

Vantage Consulting Group first reported a position in CHRS in Q4 2020 and held it in 1 quarter. The position peaked at $65K in Q4 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

Vantage Consulting Group reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 3,712 Coherus Oncology shares in Q1 2021, an estimated $65K.
Vantage Consulting Group first reported a position in Coherus Oncology in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Coherus Oncology position peaked at $65K in Q4 2020.
205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.